![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TAVT-45 (abiraterone acetate) Granules for Oral Suspension (“TAVT-45”), is an enhanced formulation of abiraterone acetate for the treatment of metastatic prostate cancer. Abiraterone inhibits testosterone production, which can suppress tumor growth.
Lead Product(s): Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: TAVT-45
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
TAVT-135, a cell-penetrating peptide conjugate, is a novel pan-genotypic chloride ion transporter intended to restore chloride ion balance and mucus hydration in patients with cystic fibrosis (CF).
Lead Product(s): TAVT-135
Therapeutic Area: Genetic Disease Product Name: TAVT-135
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2022
Details:
TAVT-45 is designed to provide an easy-to-consume oral suspension of abiraterone acetate, reconstituted in water or juice, for patients with difficulty taking large tablets.
Lead Product(s): Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: TAVT-45
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022